Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN027
MIFTS: 56

Adenomyosis

Categories: Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenomyosis

About this section

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 56 12 74 52 43 15 17
Endometriosis of Uterus 12 15 71 32
Endometriosis of Myometrium 12
Endometriosis, Myometrium 12
Endometriosis Interna 12
Uterine Adenomyosis 12

Characteristics:

OMIM:

56
Inheritance:
autosomal vs. x-linked dominant


HPO:

31
adenomyosis:
Inheritance autosomal dominant inheritance x-linked dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:288
OMIM 56 600458
ICD9CM 34 617.0
MeSH 43 D062788
NCIt 49 C6996
SNOMED-CT 67 76376003
ICD10 32 N80.0
MedGen 41 C0341858
UMLS 71 C0341858
Sources

Summaries for Adenomyosis

About this section
NIH Rare Diseases : 52 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to adenomyoma and ectopic pregnancy. An important gene associated with Adenomyosis is PGR (Progesterone Receptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Anastrozole and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include uterus, pituitary and smooth muscle, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : 12 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM : 56 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 74 Adenomyosis is a medical condition characterized by the growth of cells that build up the inside of the... more...

Sources

Related Diseases for Adenomyosis

About this section

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)
# Related Disease Score Top Affiliating Genes
1 adenomyoma 30.9 PGR MME GNRH1 ESR1 CTNNB1
2 ectopic pregnancy 30.8 VEGFA PGR HOXA10 GNRH1
3 amenorrhea 30.8 PRL GNRH1 CYP19A1
4 leiomyomatosis 30.7 PGR GNRH1 ESR1
5 intravenous leiomyomatosis 30.7 PGR MME ESR1
6 infertility 30.5 PRL PGR HOXA10 GNRH1 ESR2 CYP19A1
7 leiomyoma 30.5 PGR OXTR MME GNRH1 ESR2 ESR1
8 endometriosis of ovary 30.5 PGR GNRH1 ESR2 ESR1 CYP19A1
9 progesterone resistance 30.5 PGR ESR2 ESR1
10 leiomyosarcoma 30.4 VEGFA TP53 PGR ESR1
11 ovarian cyst 30.4 VEGFA PRL GNRH1 ESR2 CYP19A1
12 placenta accreta 30.3 OXT CTNNB1 CDH1
13 endometritis 30.3 PGR OXT ESR1 CXCL8
14 smooth muscle tumor 30.2 PGR MME ESR1
15 pre-eclampsia 30.2 VEGFA OXT MMP9 MMP2 CXCL8
16 pain agnosia 30.2 PTGS2 OXT NGF
17 ovarian hyperstimulation syndrome 30.2 VEGFA GNRH1 CYP19A1
18 preterm premature rupture of the membranes 30.1 TIMP2 OXT MMP9 MMP2 CXCL8
19 adenosarcoma 30.1 TP53 PGR MME ESR1
20 adenocarcinoma 30.1 VEGFA TP53 TIMP2 PTGS2 MMP9 MMP2
21 interstitial cystitis 30.0 VEGFA NGF CXCL8 CDH1
22 placenta disease 29.9 VEGFA OXT CXCL8
23 in situ carcinoma 29.9 TP53 PGR ESR1 CYP19A1 CTNNB1 CDH1
24 female reproductive endometrioid cancer 29.8 TP53 PGR ESR1 CTNNB1
25 leiomyoma, uterine 29.8 PGR OXT MMP2 GNRH1 ESR2 ESR1
26 neurofibromatosis, type ii 29.8 VEGFA TP53 PGR CTNNB1
27 papillary adenocarcinoma 29.8 TP53 PGR CDH1
28 endometrial adenocarcinoma 29.8 VEGFA TP53 PGR ESR2 ESR1 CTNNB1
29 tubular adenocarcinoma 29.8 PGR MME ESR1 CTNNB1 CDH1
30 vaginal discharge 29.7 PGR OXT GNRH1 ESR1 CYP19A1 CXCL8
31 hydronephrosis 29.7 VEGFA MMP9 MME CYP19A1 CXCL8
32 endometrial hyperplasia 29.6 VEGFA TP53 PGR HOXA10 ESR2 ESR1
33 ureteral obstruction 29.6 TP53 PTGS2 GNRH1 CTNNB1
34 endometriosis 29.6 VEGFA TP53 PTGS2 PGR MMP2 HOXA10
35 estrogen excess 29.4 PRL PGR GNRH1 ESR2 ESR1 CYP19A1
36 cystitis 29.3 VEGFA TP53 PTGS2 NGF CXCL8 CDH1
37 myoma 29.3 TP53 PGR OXT MME HOXA10 GNRH1
38 wilms tumor 1 29.3 VEGFA TP53 PGR ESR1 CTNNB1 CDH1
39 carcinosarcoma 29.3 TP53 PGR MME CTNNB1 CDH1
40 pelvic organ prolapse 29.2 TP53 PGR MMP9 MMP2 ESR2 ESR1
41 endometrial disease 29.2 PTGS2 PGR OXT GNRH1 ESR1 CYP19A1
42 breast fibroadenoma 29.1 TP53 TIMP2 PGR MME ESR1 CYP19A1
43 endometrial stromal sarcoma 28.6 TP53 PGR OXTR MMP9 MMP2 MME
44 uterine carcinosarcoma 28.6 TP53 PTGS2 PGR MME ESR2 ESR1
45 cervical cancer 28.6 VEGFA TP53 PTGS2 MMP9 MMP2 ESR1
46 endometrial cancer 28.1 VEGFA TP53 TIMP2 PGR MMP9 MMP2
47 ovarian cancer 27.4 VEGFA TP53 TIMP2 PTGS2 PGR MMP9
48 uterine anomalies 11.6
49 myofibroma 10.6
50 extracranial arteriovenous malformation 10.6 MMP9 MMP2

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis
Sources

Symptoms & Phenotypes for Adenomyosis

About this section

Human phenotypes related to Adenomyosis:

31
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 31 HP:0001892
2 dysmenorrhea 31 HP:0100607
3 abnormality of the genitourinary system 31 HP:0000119

Symptoms via clinical synopsis from OMIM:

56
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM:

600458

MGI Mouse Phenotypes related to Adenomyosis:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 CTNNB1 CYP19A1 ESR1 ESR2 HOXA10 MME
2 homeostasis/metabolism MP:0005376 10.47 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
3 cardiovascular system MP:0005385 10.46 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 HOXA10
4 growth/size/body region MP:0005378 10.43 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
5 endocrine/exocrine gland MP:0005379 10.41 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
6 integument MP:0010771 10.41 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
7 immune system MP:0005387 10.4 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
8 digestive/alimentary MP:0005381 10.35 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
9 hematopoietic system MP:0005397 10.33 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 MMP2
10 nervous system MP:0003631 10.33 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 HOXA10
11 muscle MP:0005369 10.23 CTNNB1 CYP19A1 ESR1 ESR2 MMP2 MMP9
12 neoplasm MP:0002006 10.21 CDH1 CTNNB1 ESR1 ESR2 GNRH1 MMP2
13 liver/biliary system MP:0005370 10.18 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 MME
14 normal MP:0002873 10.17 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
15 adipose tissue MP:0005375 10.14 CYP19A1 ESR1 ESR2 HOXA10 OXT PTGS2
16 limbs/digits/tail MP:0005371 10.1 CTNNB1 ESR1 ESR2 HOXA10 MMP9 PGR
17 no phenotypic analysis MP:0003012 10.07 CDH1 CTNNB1 ESR1 ESR2 NGF OXTR
18 reproductive system MP:0005389 10.03 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
19 renal/urinary system MP:0005367 9.96 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 MMP9
20 respiratory system MP:0005388 9.56 CTNNB1 ESR1 ESR2 MMP2 MMP9 PTGS2
21 skeleton MP:0005390 9.4 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 HOXA10
Sources

Drugs & Therapeutics for Adenomyosis

About this section

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
2
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Ibuprofen Approved Phase 4 15687-27-1 3672
5
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
6
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
7
Dienogest Approved Phase 4 65928-58-7
8
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Buserelin Approved, Investigational Phase 4 57982-77-1
12
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
13
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
14 Estrogen Antagonists Phase 4
15 Estrogen Receptor Antagonists Phase 4
16 Aromatase Inhibitors Phase 4
17 Antipyretics Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Analgesics Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Antirheumatic Agents Phase 4
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4
24 Hormone Antagonists Phase 4
25 Estrogens Phase 4
26 Hormones Phase 4
27 Contraceptives, Oral, Combined Phase 4
28 Estradiol 17 beta-cypionate Phase 4
29 Estradiol 3-benzoate Phase 4
30 Triptorelin Pamoate Phase 4
31 Antineoplastic Agents, Hormonal Phase 4
32 Contraceptive Agents, Male Phase 4
33 Contraceptives, Oral Phase 4
34 Progestins Phase 4
35
Medroxyprogesterone Phase 4 520-85-4 10631
36
Levonorgestrel Approved, Investigational Phase 3 797-63-7, 17489-40-6 13109
37
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
38
Lactitol Approved, Investigational Phase 2, Phase 3 585-88-6, 585-86-4 493591
39
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
40
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
41
Ethanol Approved Phase 2, Phase 3 64-17-5 702
42
Tranexamic Acid Approved Phase 3 1197-18-8 5526
43
Norethindrone Approved Phase 3 68-22-4 6230
44
Ramosetron Investigational Phase 3 132036-88-5
45 Neurotransmitter Agents Phase 3
46 Micronutrients Phase 3
47 Trace Elements Phase 3
48 Contraceptives, Postcoital Phase 2, Phase 3
49 Prolactin Release-Inhibiting Factors Phase 3
50 Hemostatics Phase 3

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Unknown status NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
2 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
3 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
4 Use of Oxytocin in MRI-HIFU Treatment Enrolling by invitation NCT03937401 Phase 4 Oxytocin
5 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Not yet recruiting NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
6 Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study Not yet recruiting NCT04356664 Phase 4 GnRH agonist
7 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
8 Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized Terminated NCT01776203 Phase 4 Medroxyprogesterone 17-Acetate
9 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
10 Uterine Artery Doppler and Three Dimensional Power Doppler in the Diagnosis of Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
11 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
12 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
13 Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study Unknown status NCT02437175 Phase 3
14 Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial Unknown status NCT01125488 Phase 3 GnRH agonist (triptorelin)
15 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
16 Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
17 Mifepristone Versus Placebo to Treat Adenomyosis: a Double-blind, Multicentre，Randomized Clinical Trial Completed NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
18 Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
19 Phase III Trial to Assess Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI Outcomes in Infertile Women Presenting With Adenomyosis. Not yet recruiting NCT03940807 Phase 3 11.25mg GnRH agonist;0.1 mg GnRH agonist;25 µg transdermal oestradiol
20 Single Blinded Randomized Controlled Study of Symptom Improvement After Uterine Artery Embolization (UAE) Versus Ultrasound Guided Percutaneous/Transvaginal Microwave Ablation, Evaluated by Validated Questionnaires Not yet recruiting NCT04209127 Phase 2, Phase 3
21 Effect of Tranexemic Acid and Norethisterone Acetate on Endometrial Vasculature in Women With Dysfunctional Uterine Bleeding. Not yet recruiting NCT04290013 Phase 3 norethisterone acetate;tranexamic acid tablets
22 Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis Unknown status NCT02587000 Phase 2 Ulipristal acetate;Placebo
23 Surgicel® Versus Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding (HMB): Randomised Controlled Trial Unknown status NCT03176992 Phase 2 SURGICEL®
24 Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial Completed NCT01601366 Phase 2 Combined oral contraceptives
25 Tactile Versus Hysteroscopic Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
26 A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis Recruiting NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
27 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
28 Vaginal Bromocriptine for the Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
29 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
30 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
31 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
32 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
33 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
34 Health-Related Quality of Life Among Women Receiving Hysterectomy in National Taiwan University Hospital Unknown status NCT00155870
35 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis : A Preliminary Study Unknown status NCT01259180
36 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Unknown status NCT03006406 Long term GnRH-a (3.75mg)
37 Prospective Cohort Study to Compare to 2-channel and Multiple Channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
38 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone Unknown status NCT00928044
39 "Estudio de Histerosalpingografía Por Resonancia Magnética Para la evaluación Integral de la Paciente infértil." Unknown status NCT02398630
40 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Unknown status NCT03121560
41 The Effect in Term of Ovarian Reserve Modification of Adding Prophylactic Bilateral Salpingectomy (PBS) to TLH for Preventing Ovarian Cancer Unknown status NCT02086344
42 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
43 Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Can Be Useful Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
44 The Diagnostic Accuracy of Hysteroscopic Endomyometrial Biopsy in Adenomyosis Completed NCT02340533
45 Cohort Study of Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648
46 Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part I Completed NCT02201719
47 Can the Effect of Levonorgestrel Intrauterine System for Treatment of Adenomyosis be Predicted at Baseline Visit? Completed NCT03104309
48 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
49 Short and Long Term Outcomes of Uterine Artery Embolization. Completed NCT00354471
50 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy: a Randomized, Single-Blinded Study Comparing the Efficacy to the Routine Procedure Completed NCT01806012

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Sources

Genetic Tests for Adenomyosis

About this section
Sources

Anatomical Context for Adenomyosis

About this section

MalaCards organs/tissues related to Adenomyosis:

40
Uterus, Pituitary, Smooth Muscle, Testes, Endothelial, Breast, Cervix
Sources

Publications for Adenomyosis

About this section

Articles related to Adenomyosis:

(show top 50) (show all 2654)
# Title Authors PMID Year
1
Adenomyosis: evidence for genetic cause. 61 56
7762596 1995
2
The elusive adenomyosis of the uterus. Its historical past and its present state of recognition. 61 56
13890115 1962
3
Question Mark Sign and Transvaginal Ultrasound Uterine Tenderness for the Diagnosis of Adenomyosis: A Prospective Validation. 61
32030800 2020
4
Subserosal adenomyotic cysts and peritoneal inclusion cysts - Unusual differential diagnoses of multicystic pelvic masses: A review of two cases. 61
32292709 2020
5
The prevalence of adenomyosis in an infertile population: a cross-sectional study. 61
32376315 2020
6
Adjuvant therapy of Chinese herbal medicine for the treatment of adenomyosis: A protocol for systematic review. 61
32569178 2020
7
Adenomyosis and endometriosis in adolescents and young women with pelvic pain: prevalence and risk factors. 61
32549030 2020
8
Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest. 61
31661345 2020
9
Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. 61
32507315 2020
10
The Many Faces of Endometriosis-Related Neoplasms in the Same Patient: A Brief Report. 61
32570258 2020
11
MRI image features and differential diagnoses of Herlyn-Werner-Wunderlich syndrome. 61
31657238 2020
12
Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression. 61
32046461 2020
13
Significance of changes in inflammatory parameters following uterine artery embolization in pre-menopausal females. 61
32346432 2020
14
Generating high-quality data abstractions from scanned clinical records: text-mining-assisted extraction of endometrial carcinoma pathology features as proof of principle. 61
32532784 2020
15
Tissue engineered endometrial barrier exposed to peristaltic flow shear stresses. 61
32548541 2020
16
Gynecological hysterectomy in Northern Tanzania: a cross- sectional study on the outcomes and correlation between clinical and histological diagnoses. 61
32532271 2020
17
Evaluation of adenomyosis after gonadotrophin-releasing hormone agonist therapy using ultrasound post-processing imaging: a pilot study. 61
32536293 2020
18
Pregnancy and Its Outcome in a Rare Case of Combined Protein C and Protein S Deficiency with Severe Adenomyosis. 61
32476772 2020
19
Rapid Effects of Oestrogen on Intracellular Ca2+ in the Uterine Junctional Myometrium of Patients With and Without Adenomyosis in Different Phases of the Menstrual Cycle. 61
32542538 2020
20
Abnormal uterine bleeding and the risk of endometrial cancer: Can subendometrial vascular ultrasound be of help to discriminate cancer from adenomyosis? 61
32497607 2020
21
Hysteroscopic treatment of symptomatic adenomyoma 61
31245966 2020
22
Adenomyotic glands are highly related to endometrial glands. 61
32362572 2020
23
Adenomyosis presenting as a molar pregnancy: A case report. 61
32373693 2020
24
The association between adenomyosis and recurrent miscarriage. 61
32428805 2020
25
Asherman syndrome in adenomyosis treated with uterine artery embolization: incidence predictive factors. 61
32020527 2020
26
Acute cerebral infarction with adenomyosis in a patient with fever: a case report. 61
32450843 2020
27
Laparoscopic treatment of a large cystic adenomyosis of the uterus: A case report. 61
32460088 2020
28
Uterine adenomyosis with extensive glandular proliferation: case series of a rare imaging variant. 61
32209513 2020
29
Long-term efficacy and feasibility of levonorgestrel-releasing intrauterine device use in patients with adenomyosis. 61
32481439 2020
30
Pathophysiologic mechanisms by which adenomyosis predisposes to postpartum haemorrhage and other obstetric complications. 61
32498005 2020
31
Patient perceptions of misdiagnosis of endometriosis: results from an online national survey. 61
32007945 2020
32
Comparison between transumbilical and transvaginal morcellation of a large uterus during single-port-access total laparoscopic hysterectomy. 61
32489984 2020
33
Fertility Outcomes After Laparoscopic Cystectomy in Infertile Patients with Stage III-IV Endometriosis: a Cohort with 6-10 years of Follow-up. 61
32200536 2020
34
Histologic findings in hysterectomies after endometrial ablation. 61
32475645 2020
35
TIPE2 inhibits the migration and invasion of endometrial cells by targeting β-catenin to reverse epithelial-mesenchymal transition. 61
32469403 2020
36
Overexpression of Lin28B Promoted the Proliferation of Adenomyotic Smooth Muscle Cells of the Junctional Zone via Regulating Let-7a. 61
32046465 2020
37
The role of levonorgestrel intra-uterine system in the management of adenomyosis: A systematic review and meta-analysis of prospective studies. 61
31889294 2020
38
Celecoxib, a selective COX-2 inhibitor, markedly reduced the severity of tamoxifen-induced adenomyosis in a murine model. 61
32266025 2020
39
The Effects of Anti-TGF-β1 on Epithelial-Mesenchymal Transition in the Pathogenesis of Adenomyosis. 61
32253735 2020
40
Endometrial cancer arising from adenomyosis: Case report and literature review of MRI findings. 61
32099587 2020
41
The importance of transient myometrial contractions in the diagnosis of adenomyosis and congenital uterine anomalies. 61
32250499 2020
42
Expression and significance of T-cell immunoglobulin mucin molecule 3 and its ligand galectin-9 in patients with adenomyosis. 61
32319832 2020
43
Malignant risk of pelvic mass after hysterectomy for adenomyosis or endometriosis. 61
32282727 2020
44
G protein-coupled estrogen receptor 1 expression in normal myometrium, leiomyoma, and adenomyosis tissues of premenopausal women. 61
32321334 2020
45
Clinical outcomes of hysterectomy for benign diseases in the female genital tract: 6 years' experience in a single institute. 61
32326683 2020
46
Laparoscopic gynecological surgery in an adult woman with Becker muscular dystrophy performed with sevoflurane with cisatracurium anesthesia: A case report. 61
32311965 2020
47
Diagnosing adenomyosis: an integrated clinical and imaging approach. 61
32097456 2020
48
Dysmenorrhea in patients with adenomyosis: A clinical and demographic study. 61
32325268 2020
49
Exploring the challenges for a new classification of adenomyosis. 61
32173239 2020
50
A Comparison of Hysterectomies for Bleeding With Hysterectomies for Pain. 61
31612752 2020
Sources

Variations for Adenomyosis

About this section
Sources

Expression for Adenomyosis

About this section
Search GEO for disease gene expression data for Adenomyosis.
Sources

Pathways for Adenomyosis

About this section

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.03 VEGFA TP53 TIMP2 PTGS2 PRL MMP9
2
ERK Signaling 63
Show member pathways
 13.77 VEGFA TP53 TIMP2 PTGS2 NGF GNRH1
3
GPCR Pathway 63
Show member pathways
 13.68 VEGFA TP53 TIMP2 PTGS2 NGF MMP9
4
TGF-Beta Pathway 63
Show member pathways
 13.52 VEGFA TP53 TIMP2 PRL NGF GNRH1
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.34 VEGFA TP53 PTGS2 PRL MMP9 MMP2
6
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.26 VEGFA TIMP2 NGF GNRH1 ESR2 ESR1
7
PI3K-Akt signaling pathway 36
Show member pathways
 12.98 VEGFA TP53 PTGS2 PRL NGF CTNNB1
8
Gastric cancer 36
Show member pathways
 12.77 TP53 PGR ESR2 ESR1 CTNNB1 CDH1
9
Development HGF signaling pathway 22
Show member pathways
 12.69 TP53 PTGS2 NGF ESR1 CTNNB1 CDH1
10
Glioma 36
Show member pathways
 12.65 TP53 MMP9 MMP2 ESR2 ESR1 CDH1
11
Relaxin signaling pathway 36
Show member pathways
 12.64 VEGFA PGR MMP9 MMP2 ESR2 ESR1
12
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.38 VEGFA PTGS2 ESR1 CTNNB1
13
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.38 TIMP2 NGF GNRH1 CTNNB1 CDH1
14
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.27 TP53 TIMP2 NGF GNRH1 CXCL8
15
Proteoglycans in cancer 36
12.27 VEGFA TP53 MMP9 MMP2 ESR1 CTNNB1
16
Transcriptional misregulation in cancer 36
12.26 TP53 MMP9 HOXA10 CXCL8
17
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.14 VEGFA NGF ESR2 CXCL8 CTNNB1
18
Pathways in cancer 36
12.05 VEGFA TP53 PTGS2 MMP9 MMP2 ESR2
19
Fluid shear stress and atherosclerosis 36
12.04 VEGFA TP53 MMP9 MMP2 CTNNB1
20
Adhesion 4
12.03 MMP9 MMP2 CTNNB1 CDH1
21
Integrated Breast Cancer Pathway 1
12.03 VEGFA TP53 ESR1 CYP19A1 CTNNB1 CDH1
22
Spinal Cord Injury 1
12.01 TP53 PTGS2 MMP9 CXCL8
23
Colorectal Cancer Metastasis 63
11.92 VEGFA TP53 PTGS2 MMP9 MMP2 CTNNB1
24
Angiogenesis (CST) 4
11.84 TIMP2 PTGS2 MMP9 MMP2
25
Interleukin-4 and 13 signaling 65
11.79 VEGFA TP53 PTGS2 MMP9 MMP2 CXCL8
26
Glucocorticoid receptor regulatory network 1
11.78 TP53 PRL CXCL8
27
Transcription_P53 signaling pathway 22
11.7 VEGFA TP53 MMP2 CTNNB1
28
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.7 MMP9 MMP2 CXCL8 CTNNB1 CDH1
29
LPA receptor mediated events 1
11.67 MMP9 MMP2 CXCL8
30
Lung fibrosis 1
11.65 MMP9 MMP2 CXCL8
31
Cell adhesion_ECM remodeling 22
11.63 TIMP2 MMP9 MMP2 CXCL8
32
Celecoxib Pathway, Pharmacodynamics 60
11.59 VEGFA PTGS2 MMP9 CTNNB1
33
Aryl Hydrocarbon Receptor 1
11.52 VEGFA PTGS2 ESR1
34
Hepatitis C and Hepatocellular Carcinoma 1
11.52 VEGFA TP53 PTGS2 CXCL8
35
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.52 VEGFA PTGS2 MMP9 MMP2 CXCL8
36
Photodynamic therapy-induced HIF-1 survival signaling 1
11.4 VEGFA TP53 PTGS2
37
Signaling mediated by p38-alpha and p38-beta 1
11.37 TP53 PTGS2 ESR1
38
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.35 MMP9 MMP2 CXCL8
39
Ovarian Infertility Genes 1
11.32 PGR ESR2 CYP19A1
40
A-beta Uptake and Degradation 64
11.31 MMP9 MMP2 MME
41
Bladder cancer 36 1
11.3 VEGFA TP53 MMP9 MMP2 CXCL8 CDH1
42
Angiogenesis (WikiPathways) 1
11.17 VEGFA TIMP2 MMP9
43
Plasma membrane estrogen receptor signaling 1
11.17 MMP9 MMP2 ESR2 ESR1
44
A-beta Plaque Formation and APP Metabolism 64
11.14 MMP9 MMP2 MME
45
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 60
10.21 ESR2 ESR1 CYP19A1
Sources

GO Terms for Adenomyosis

About this section

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA TIMP2 PRL OXT NGF MMP9
2 extracellular space GO:0005615 9.28 VEGFA TIMP2 PRL OXT NGF MMP9
3 flotillin complex GO:0016600 9.16 CTNNB1 CDH1

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 VEGFA PRL PGR OXTR OXT GNRH1
2 positive regulation of apoptotic process GO:0043065 9.99 TP53 PTGS2 NGF MMP9 CTNNB1
3 heart development GO:0007507 9.97 TP53 OXTR OXT CTNNB1
4 aging GO:0007568 9.92 TIMP2 PTGS2 MME GNRH1
5 negative regulation of gene expression GO:0010629 9.92 VEGFA TP53 PGR ESR1 CTNNB1
6 negative regulation of apoptotic process GO:0043066 9.87 VEGFA TP53 PTGS2 NGF MMP9 GNRH1
7 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.83 VEGFA PTGS2 NGF
8 extracellular matrix disassembly GO:0022617 9.81 TIMP2 MMP9 MMP2
9 response to peptide hormone GO:0043434 9.8 OXTR OXT GNRH1
10 response to cytokine GO:0034097 9.8 TIMP2 PTGS2 OXTR
11 response to organic cyclic compound GO:0014070 9.8 PTGS2 OXTR OXT GNRH1
12 lactation GO:0007595 9.73 VEGFA PRL OXTR
13 female pregnancy GO:0007565 9.73 PRL OXTR OXT GNRH1
14 response to drug GO:0042493 9.73 TP53 TIMP2 PTGS2 OXTR CTNNB1 CDH1
15 embryo implantation GO:0007566 9.72 PTGS2 MMP9 MMP2
16 memory GO:0007613 9.71 PTGS2 OXTR OXT NGF
17 mammary gland development GO:0030879 9.69 PRL PGR CYP19A1
18 regulation of neuroinflammatory response GO:0150077 9.66 PTGS2 MMP9
19 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.66 TP53 ESR1
20 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.65 TP53 ESR1
21 entry of bacterium into host cell GO:0035635 9.65 CTNNB1 CDH1
22 response to steroid hormone GO:0048545 9.65 OXTR OXT GNRH1
23 response to prostaglandin E GO:0034695 9.64 OXT GNRH1
24 positive regulation of uterine smooth muscle contraction GO:0070474 9.63 OXTR OXT
25 cytokine-mediated signaling pathway GO:0019221 9.63 VEGFA TP53 PTGS2 MMP9 MMP2 CXCL8
26 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.61 VEGFA TP53
27 negative regulation of gastric acid secretion GO:0060455 9.61 OXTR OXT
28 cellular response to indole-3-methanol GO:0071681 9.58 CTNNB1 CDH1
29 positive regulation of penile erection GO:0060406 9.58 OXTR OXT
30 sperm ejaculation GO:0042713 9.57 OXTR OXT
31 positive regulation of norepinephrine secretion GO:0010701 9.54 OXTR OXT
32 uterus development GO:0060065 9.54 HOXA10 ESR1 CYP19A1
33 negative regulation of cell proliferation GO:0008285 9.5 TP53 TIMP2 PTGS2 NGF GNRH1 CXCL8
34 regulation of digestive system process GO:0044058 9.46 OXTR OXT
35 response to estradiol GO:0032355 9.1 PTGS2 OXTR OXT ESR1 CYP19A1 CTNNB1

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.2 TP53 TIMP2 PTGS2 PGR MMP9 MMP2
2 enzyme binding GO:0019899 9.63 TP53 PTGS2 PGR ESR2 ESR1 CTNNB1
3 steroid hormone receptor activity GO:0003707 9.61 PGR ESR2 ESR1
4 zinc ion binding GO:0008270 9.56 TP53 TIMP2 PGR MMP9 MMP2 MME
5 nuclear receptor activity GO:0004879 9.54 PGR ESR2 ESR1
6 steroid binding GO:0005496 9.43 PGR ESR2 ESR1
7 estrogen receptor activity GO:0030284 9.4 ESR2 ESR1
8 estrogen response element binding GO:0034056 9.32 ESR2 ESR1
9 repressing transcription factor binding GO:0070491 8.92 PGR ESR2 ESR1 CTNNB1
Sources

Sources for Adenomyosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....